Alexander Shneider

Part of Curelab Veterinary, Inc., CureLab Oncology, Inc. is a pre-IPO, clinical-stage biotech company headquartered in the greater area. The company is based in Boston, MA. The company is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. CureLab Oncology is developing an experimental DNA therapy called p62/sqstm1, which consists of a circular piece of DNA called a plasmid that includes a gene for a human protein. The company was founded by Alexander Shneider, who has been the CEO since incorporation.

Part of Curelab Veterinary, Inc., CureLab Oncology, Inc. is a pre-IPO, clinical-stage biotech company headquartered in the greater area. The company is based in Boston, MA. The company is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. CureLab Oncology is developing an experimental DNA therapy called p62/sqstm1, which consists of a circular piece of DNA called a plasmid that includes a gene for a human protein. The company was founded by Alexander Shneider, who has been the CEO since incorporation.

Part of Curelab Veterinary, Inc., CureLab Oncology, Inc. is a pre-IPO, clinical-stage biotech company headquartered in the greater area. The company is based in Boston, MA. The company is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. CureLab Oncology is developing an experimental DNA therapy called p62/sqstm1, which consists of a circular piece of DNA called a plasmid that includes a gene for a human protein. The company was founded by Alexander Shneider, who has been the CEO since incorporation.